A Single-center, Randomized, Double-blind, Single Oral Dose, Placebo-controlled Study to Evaluate the Effect of MY008211A Tablets on QTc Interval in Healthy Chinese Adult Subjects
Latest Information Update: 12 Aug 2024
At a glance
- Drugs MY-008211A (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Therapeutic Use
- Sponsors Wuhan Createrna Science and Technology
- 12 Aug 2024 New trial record